Repurposing tirbanibulin as an orally active E2-targeting entry inhibitor against Chikungunya virus.
BACKGROUND AND PURPOSE Chikungunya virus (CHIKV) causes severe acute and chronic disease, yet no approved specific antiviral treatment exists. To rapidly identify potential treatments, we aimed to screen an FDA-approved drug library for inhibitors of CHIKV infection. Tirbanibulin, a dual-microtubule polymerization and...